Medicure Inc. (FRA:NGQ1)

Market Cap	7.49M
Revenue (ttm)	16.04M
Net Income (ttm)	-2.10M
Shares Out	n/a
EPS (ttm)	-0.20
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	404
Open	0.6950
Previous Close	0.6950
Day's Range	0.6950 - 0.6950
52-Week Range	0.3660 - 0.8400
Beta	n/a
RSI	49.53
Earnings Date	Apr 28, 2026

About Medicure

Medicure Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human therapies in the United States. The company markets AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia. In addition, the company is developing MC-1 for the treatment of PNPO deficiency; and TARDOXAL for neurological i...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1997
• Employees: 38
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: NGQ1

Financial Performance

In 2024, Medicure's revenue was 21.91 million, an increase of 0.98% compared to the previous year's 21.69 million. Losses were -1.04 million, 12.7% more than in 2023.

Financial numbers in CAD